European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation, Europace, vol.15, issue.5, pp.625-651, 2013. ,
DOI : 10.1093/europace/eut083
« Dabigatran versus warfarin in the treatment of acute venous thromboembolism, New England Journal of Medicine, vol.361, issue.24, pp.2345-52, 2009. ,
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation, Rivaroxaban versus warfarin in non valvular atrial fibrillation, pp.883-91, 2011. ,
DOI : 10.1056/NEJMoa1009638
URL : https://hal.archives-ouvertes.fr/hal-01038111
Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial, The Lancet, vol.372, issue.9632, pp.31-39, 2008. ,
DOI : 10.1016/S0140-6736(08)60880-6
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty, New England Journal of Medicine, vol.358, issue.26, pp.2776-2786, 2008. ,
DOI : 10.1056/NEJMoa076016
« Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4) : a randomised trial, pp.1673-80, 1016. ,
A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment, doi: 10.2147/VHRM.S30064, pp.363-7094, 2012. ,
A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study, American Heart Journal, vol.169, issue.5, pp.597-604, 2015. ,
DOI : 10.1016/j.ahj.2015.02.009
Direct Factor Xa Inhibitor, in Humans » , Drug Metabolism et Disposition, pp.2250-2255, 2012. ,
Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation, Thrombosis and Haemostasis, vol.104, issue.3, pp.633-64, 2010. ,
DOI : 10.1160/TH10-01-0066
Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation, Thrombosis and Haemostasis, vol.107, issue.5, pp.925-961, 2012. ,
DOI : 10.1160/TH11-08-0566
Dabigatran etexilate ? a novel, reversible, oral direct thrombin inhibitor : Interpretation of coagulation assays and reversal of anticoagulant activity, Thrombosis and Haemostasis, vol.103, issue.6, pp.1116-1127, 2010. ,
« Les anticoagulants oraux directs dans la pratique médicale: implications pour le laboratoire d'hémostase », Pipette -swiss laboratory medicine, pp.17-18, 2014. ,
« On the monitoring of dabigatran treatment in'real life' patients with atrial fibrillation, Thrombosis Research, vol.134, issue.4, pp.783-789, 2014. ,
Sylvie Labrouche, « Performance of three functional assays for the measurement of dabigatran plasma concentrations, p.2015 ,
« Performance of three functional assays for the measurement of dabigatran plasma concentrations, pp.15-1112 ,
An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma, Thrombosis and Haemostasis, vol.104, issue.5, pp.1078-1079, 2010. ,
DOI : 10.1160/TH10-03-0204
Des anciens tests de coagulation ?? ceux plus r??cents, Bio tribune magazine, vol.113, issue.1, 2011. ,
DOI : 10.1007/s11834-011-0050-z
Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement, Accidents hémorragiques sous anticoagulants oraux (AVK et AOD) aux urgences du CHU de Bordeaux : étude de cohorte rétrospective », thèse du 25 septembre 2015 (74), pp.457-465, 2011. ,
« Gestion des Anticoagulants Oraux Directs pour la chirurgie et les actes invasifs programmés : propositions réactualisées du Groupe d'Intérêt en Hémostase Périopératoire (GIHP), 2015. ,
insertion progressive de la carte de surveillance du patient dans les conditionnements », Le Vidal, rubrique « actualités ,
Antagonisation des héparines et des nouveaux anticoagulants », Annales françaises d'anesthésie et de réanimation, pp.37-49, 2013. ,
« Effect of noon-specifique reversal agents on anticoagulant activity of dabigatran and rivaroxaban : a randomised crossover ex vivo study in healthy volunteers, Thrombosis Haemostasis, pp.217-224, 2012. ,
« Reversal of apixaban induced alterations in haemostasis by different coagulation factor concentrates : signature of studies in vitro with circulation human blood, PloS One, 2013. ,
Effect of Activated Charcoal on Apixaban Pharmacokinetics in Healthy Subjects, American Journal of Cardiovascular Drugs, vol.113, issue.4, pp.147-154, 2014. ,
DOI : 10.1007/s40256-013-0055-y
« A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. » Thrombosis Haemostasis, pp.943-51 ,
Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran, Thrombosis and Haemostasis, vol.114, issue.1, pp.198-205, 2015. ,
DOI : 10.1160/TH15-03-0192
«Protocole d'utilisation thérapeutique et de recueil d'information, ATU de cohorte de l'Idarucizumab, pp.6-2015 ,
A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa, Nature Medicine, vol.48, issue.4, pp.446-51, 2013. ,
DOI : 10.1038/nm.3102
Use of PER977 to Reverse the Anticoagulant Effect of Edoxaban, Use of PER977 to reverse the anticoagulant effect of edoxaban, pp.2141-2143, 2014. ,
DOI : 10.1056/NEJMc1411800
« Switching from a vitamin K antagonist to a NOAC », The Lancet haematology, 2015. ,
Novel antidotes for target specific oral anticoagulants, Experimental Hematology & Oncology, vol.371, issue.22, p.2015 ,
DOI : 10.1186/s40164-015-0020-3
« Safety and eff ectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, noninterventional study, Lancet Haematol, vol.3, pp.12-14, 2016. ,